Tingting Hu, Jinbo Zhan, Li Li, Yan He, Yun Lin, Jingru Wang, Haiming Yu, Jianping Xiong, Ziling Fang, Jun Deng, Shanshan Huang, Xiaojun Xiang
Anaplastic lymphoma kinase (ALK) rearrangement is a well-known driver oncogene detected in approximately 5% of non-small cell lung cancer. However, ALK rearrangement is much less frequent in other solid tumors outside the lungs, such as colorectal cancer (CRC); thus, the optimal management of CRC with ALK rearrangements has yet to be established. In this report, we describe 2 cases of ALK-positive CRC, both of which benefited from ALK tyrosine kinase inhibitor (ALK-TKI) therapy. Case 1 was a postoperative patient with poorly differentiated colon adenocarcinoma, who was diagnosed with metastatic relapse shortly after surgery...
February 21, 2024: Oncologist